Dataset Information

APP intracellular domain derived from amyloidogenic ?- and ?-secretase cleavage regulates neprilysin expression.

ABSTRACT: Alzheimer's disease (AD) is characterized by an accumulation of Amyloid-? (A?), released by sequential proteolytic processing of the amyloid precursor protein (APP) by ? - and ?-secretase. A? peptides can aggregate, leading to toxic A? oligomers and amyloid plaque formation. A? accumulation is not only dependent on de novo synthesis but also on A? degradation. Neprilysin (NEP) is one of the major enzymes involved in A? degradation. Here we investigate the molecular mechanism of NEP regulation, which is up to now controversially discussed to be affected by APP processing itself. We found that NEP expression is highly dependent on the APP intracellular domain (AICD), released by APP processing. Mouse embryonic fibroblasts devoid of APP processing, either by the lack of the catalytically active subunit of the ?-secretase complex [presenilin (PS) 1/2] or by the lack of APP and the APP-like protein 2 (APLP2), showed a decreased NEP expression, activity and protein level. Similar results were obtained by utilizing cells lacking a functional AICD domain (APP?CT15) or expressing mutations in the genes encoding for PS1. AICD supplementation or retransfection with an AICD encoding plasmid could rescue the down-regulation of NEP further strengthening the link between AICD and transcriptional NEP regulation, in which Fe65 acts as an important adaptor protein. Especially AICD generated by the amyloidogenic pathway seems to be more involved in the regulation of NEP expression. In line, analysis of NEP gene expression in vivo in six transgenic AD mouse models (APP and APLP2 single knock-outs, APP/APLP2 double knock-out, APP-swedish, APP-swedish/PS1?exon9, and APP?CT15) confirmed the results obtained in cell culture. In summary, in the present study we clearly demonstrate an AICD-dependent regulation of the A?-degrading enzyme NEP in vitro and in vivo and elucidate the underlying mechanisms that might be beneficial to develop new therapeutic strategies for the treatment of AD.

SUBMITTER: Grimm MO

PROVIDER: S-EPMC4443740 | biostudies-literature | 2015

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

APP intracellular domain derived from amyloidogenic β- and γ-secretase cleavage regulates neprilysin expression.

Grimm Marcus O W MO Mett Janine J Stahlmann Christoph P CP Grösgen Sven S Haupenthal Viola J VJ Blümel Tamara T Hundsdörfer Benjamin B Zimmer Valerie C VC Mylonas Nadine T NT Tanila Heikki H Müller Ulrike U Grimm Heike S HS Hartmann Tobias T

Frontiers in aging neuroscience 20150519

Alzheimer's disease (AD) is characterized by an accumulation of Amyloid-β (Aβ), released by sequential proteolytic processing of the amyloid precursor protein (APP) by β - and γ-secretase. Aβ peptides can aggregate, leading to toxic Aβ oligomers and amyloid plaque formation. Aβ accumulation is not only dependent on de novo synthesis but also on Aβ degradation. Neprilysin (NEP) is one of the major enzymes involved in Aβ degradation. Here we investigate the molecular mechanism of NEP regulation, w ...[more]

PMID: 26074811

Similar Datasets

Project description:BACKGROUND:γ-Secretase is a multiprotein protease that cleaves amyloid protein precursor (APP) and other type I transmembrane proteins. It has two catalytic subunits, presenilins 1 and 2 (PS1 and 2). In our previous report, we observed subtle differences in PS1- and PS2-mediated cleavages of select substrates and slightly different potencies of PS1 versus PS2 inhibition for select γ-secretase inhibitors (GSIs) on various substrates. In this study, we investigated whether γ-secretase modulators (GSMs) and inverse γ-secretase modulators (iGSMs) modulate γ-secretase processivity using multiple different substrates. We next used HEK 293T cell lines in which PSEN1 or PSEN2 was selectively knocked out to investigate processivity and response to GSMs and iGSMs. METHODS:For cell-free γ-secretase cleavage assay, recombinant substrates were incubated with CHAPSO-solubilized CHO or HEK 293T cell membrane with GSMs or iGSMs in suitable buffer. For cell-based assay, cDNA encoding substrates were transfected into HEK 293T cells. Cells were then treated with GSMs or iGSMs, and conditioned media were collected. Aβ and Aβ-like peptide production from cell-free and cell-based assay were measured by ELISA and mass spectrometry. RESULT:These studies demonstrated that GSMs are highly selective for effects on APP, whereas iGSMs have a more promiscuous effect on many substrates. Surprisingly, iGSMs actually appear to act as like GSIs on select substrates. The data with PSEN1 or PSEN2 knocked out HEK 293T reveal that PS1 has higher processivity and response to GSMs than PS2, but PS2 has higher response to iGSM. CONCLUSION:Collectively, these data indicate that GSMs are likely to have limited target-based toxicity. In addition, they show that iGSMs may act as substrate-selective GSIs providing a potential new route to identify leads for substrate-selective inhibitors of certain γ-secretase-mediated signaling events. With growing concerns that long-term β-secretase inhibitor is limited by target-based toxicities, such data supports continued development of GSMs as AD prophylactics.

Dataset Information

APP intracellular domain derived from amyloidogenic ?- and ?-secretase cleavage regulates neprilysin expression.

Publications

APP intracellular domain derived from amyloidogenic β- and γ-secretase cleavage regulates neprilysin expression.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets